Pharmaceutical Business Review
Published:27-February-2009
By Datamonitor staff writer
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and Ambrx, a biopharmaceutical company, have announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis.
ARX424 was created by Ambrx through the application of its proprietary protein optimization technology, ReCODE. This second collaboration between the two companies follows a previous agreement announced in 2007 to develop ARX201, Ambrx's long-acting growth hormone product, currently in Phase II of clinical development.
.Published:27-February-2009
By Datamonitor staff writer
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and Ambrx, a biopharmaceutical company, have announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis.
ARX424 was created by Ambrx through the application of its proprietary protein optimization technology, ReCODE. This second collaboration between the two companies follows a previous agreement announced in 2007 to develop ARX201, Ambrx's long-acting growth hormone product, currently in Phase II of clinical development.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
0 comments:
Post a Comment